Skip to content

Arvinas ARVN Earnings yield

Earnings yield at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-18%+0.2pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-4.6%-1.8pp
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-9.9%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-8.1%-4.0pp
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-13.3%+13.4pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-14.2%-3.3pp

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's earnings yield?
Arvinas (ARVN) reported earnings yield of -32.6% in Q1 2026.
How has Arvinas's earnings yield changed year-over-year?
Arvinas's earnings yield decreased by 238.2% year-over-year, from -9.7% to -32.6%.
What is the long-term trend for Arvinas's earnings yield?
Over 5 years (2020 to 2025), Arvinas's earnings yield has grown at a 31.9% compound annual growth rate (CAGR), from -2.7% to -10.6%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.